Medical Week Daily

Medical news today: Monday, November 9, 2026

FDA investigates malignancy reports after Zolgensma; MHRA issues interim monitoring advice for givinostat; regulators update cell and gene therapy guidance

Get tomorrow's issue in your inbox.

  1. 01

    FDA finalises potency-assurance guidance for cell and gene therapies

    Source: US FDA

    A November 6 regulatory roundup reports the FDA issued final guidance describing a science- and risk-based approach to potency assurance across the lifecycle of cellular and gene therapy products. The recommendations cover development, manufacturing controls, analytical methods and post-approval monitoring, with attention to product-specific variability and evidence that each batch has the intended biological activity.

    Why it mattersPotency is central to demonstrating that complex biologic and gene-therapy products consistently deliver their intended effect. The guidance is relevant to CMC strategy, assay qualification, batch release and lifecycle control planning. More on Approvals & regulatory →

  2. 02

    FDA grants accelerated approval to Rybrevant Faspro for recurrent or metastatic head and neck cancer

    Source: US FDA

    A November 6 regulatory roundup reports the FDA granted accelerated approval to amivantamab and hyaluronidase-lpuj (Rybrevant Faspro) for adults with recurrent or metastatic head and neck squamous cell carcinoma after progression on platinum-based chemotherapy and immunotherapy. The reported supporting evidence included an objective response rate of 42% in 102 patients; confirmatory studies are required to verify clinical benefit.

    Why it mattersThe approval is a regulatory milestone for a population with limited options after prior treatment. Because it is accelerated approval, follow-up evidence and confirmatory trial outcomes remain important to the benefit-risk assessment. More on Approvals & regulatory →

  3. 03

    FDA investigates malignancy reports linked to Zolgensma gene therapy

    Source: US FDA

    The FDA said it is investigating postmarketing reports of malignancies in patients treated with onasemnogene abeparvovec (Zolgensma) for spinal muscular atrophy. The agency described reports involving several tumour sites and confirmed cases of vector DNA integration involving the GLI1 oncogene. The FDA is evaluating the evidence; this is an investigation, not a new conclusion that every reported tumour was caused by treatment.

    Why it mattersThis is an important postmarketing safety topic for gene-therapy pharmacovigilance. Case assessment should distinguish spontaneous reports, molecular evidence and confirmed causal attribution, while clinicians and families should follow current product information and regulator communications. More on Approvals & regulatory →

  4. 04

    MHRA issues interim risk-mitigation advice for givinostat after reports of deaths

    Source: MHRA / GOV.UK

    The MHRA reported several international deaths in patients with Duchenne muscular dystrophy receiving givinostat and issued interim risk-mitigation advice pending further review. The advice includes enhanced ECG and electrolyte monitoring at specified points. The agency stated that no UK deaths had been reported in the notice and advised patients not to stop prescribed treatment without speaking to their specialist.

    Why it mattersThe update illustrates how emerging postmarketing safety information can lead to targeted monitoring while a regulator reviews the evidence. Pharmacovigilance teams should track the source notice, product information changes and any subsequent regulatory communication. More on Approvals & regulatory →

New here? How to read this digest
Each story links to its original source. "Why it matters" explains what it means for you in plain language. This is news, not medical advice: talk to your doctor about your own care. Browse all topics or the archive.

More recent digests

Free daily email

The day's approvals, safety signals and trials, in five minutes.

Join the list with just your email. You can also follow the RSS feed.

Free, one field, no spam. We only use your address to send Medical Week Daily and never sell it. Ask to be removed any time via the contact page. See the privacy note.

For information and education only. Not medical advice. Medical Week Daily summarizes published health news in plain language for general readers. It does not replace advice from your doctor, product labeling or regulatory documents. Always consult a qualified healthcare professional about your own care, and check the original source. Full medical disclaimer